# Elevated anti-apoptotic shift in primary human aniridia limbal stromal cells following 48 hours supraphysiological glucose exposure, in vitro

**Authors:** Shanhe Liu, Shuailin Li, Shao-Lun Hsu, Fabian N. Fries, Zhen Li, Swarnali Kundu, Berthold Seitz, Maryam Amini, Shweta Suiwal, Tanja Stachon, Nóra Szentmáry

PMC · DOI: 10.1371/journal.pone.0340117 · PLOS One · 2026-01-12

## TL;DR

High glucose levels reduce cell death in limbal stromal cells, especially in those from aniridia patients, suggesting a protective response to metabolic stress.

## Contribution

The study reveals a novel anti-apoptotic shift in aniridia-derived limbal cells under high glucose, linking it to potential therapeutic strategies.

## Key findings

- High glucose significantly reduced apoptosis in both LSCs and AN-LSCs.
- High glucose upregulated anti-apoptotic genes like XIAP and BIRC5 in both cell types.
- AN-LSCs showed additional reductions in CASP3 and CDKN1A, with lower BAX levels compared to LSCs under high glucose.

## Abstract

Previous work demonstrated that supraphysiological glucose remodels TGF-β1 and NF-κB signaling in human limbal stromal cells (LSCs) and congenital aniridia-derived LSCs (AN-LSCs). The present study investigated whether the same metabolic stress also alters apoptotic pathways in these cells.

Primary LSCs (n = 12) and AN-LSCs (n = 8) were cultured for 48 hours in DMEM containing either normal (17.5 mM) or high (70 mM) glucose. Apoptosis was quantified by Annexin V/propidium iodide (PI) flow cytometry (FC). Expression levels of apoptosis-related genes—including CASP3/7/8/9/10, BCL2, BID, BAX, CDKN1A (p21), CDKN1B (p27), TNFα, XIAP, and BIRC5 (Survivin)—were assessed by qPCR. Protein levels of these markers were analyzed by FC, and TNFα protein concentrations in culture supernatants were measured by ELISA.

High glucose significantly reduced the proportion of apoptotic cells in both LSCs (p = 0.0170) and AN-LSCs (p = 0.0181). In both cell types, CASP8 (p = 0.0448; p = 0.0171) and CASP10 (p = 0.0001; p = 0.0007) mRNA levels decreased, while XIAP (p = 0.0375; p = 0.0442) and BIRC5 (p = 0.0196; p = 0.0003) were upregulated. AN-LSCs additionally showed reductions in CASP3 (p = 0.0138) and CDKN1A (p = 0.0331), and exhibited lower BAX levels than LSCs under high glucose (p = 0.0255). Protein analysis corroborated these findings in AN-LSCs: Caspase-3 (p = 0.0154) and Caspase-8 (p = 0.0257) decreased, while Bcl-2 (p = 0.0284) and Survivin (p = 0.0467) levels increased. XIAP protein levels rose in both LSCs (p = 0.0451) and AN-LSCs (p = 0.0134).

A 48-hour exposure to 70 mM glucose induces a marked anti-apoptotic shift in human limbal stromal cells, more pronounced in cells derived from congenital aniridia patients. Together with previous evidence on TGF-β1 and NF-κB regulation, these findings suggest that limbal cells may mount an early protective response to metabolic stress, which could be harnessed therapeutically to manage aniridia-associated keratopathy through coordinated survival and stress pathways.

## Linked entities

- **Genes:** CASP3 (caspase 3) [NCBI Gene 836], CASP7 (caspase 7) [NCBI Gene 840], CASP8 (caspase 8) [NCBI Gene 841], CASP9 (caspase 9) [NCBI Gene 842], CASP10 (caspase 10) [NCBI Gene 843], BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596], BID (BH3 interacting domain death agonist) [NCBI Gene 637], BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581], CDKN1A (cyclin dependent kinase inhibitor 1A) [NCBI Gene 1026], CDKN1B (cyclin dependent kinase inhibitor 1B) [NCBI Gene 1027], TNF (tumor necrosis factor) [NCBI Gene 7124], XIAP (X-linked inhibitor of apoptosis) [NCBI Gene 331], BIRC5 (baculoviral IAP repeat containing 5) [NCBI Gene 332]
- **Proteins:** Casp3 (caspase 3), casp8 (caspase 8, apoptosis-related cysteine peptidase), BCL2 (BCL2 apoptosis regulator), birc5a (baculoviral IAP repeat containing 5a), XIAP (X-linked inhibitor of apoptosis)
- **Diseases:** aniridia (MONDO:0019172)
- **Species:** Homo sapiens (taxon 9606)

## Full-text entities

- **Genes:** BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581] {aka BCL2L4}, CDKN1B (cyclin dependent kinase inhibitor 1B) [NCBI Gene 1027] {aka CDKN4, KIP1, MEN1B, MEN4, P27KIP1}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, DCTN6 (dynactin subunit 6) [NCBI Gene 10671] {aka WS-3, WS3, p27}, XIAP (X-linked inhibitor of apoptosis) [NCBI Gene 331] {aka API3, BIRC4, IAP-3, ILP1, MIHA, XLP2}, ANXA5 (annexin A5) [NCBI Gene 308] {aka ANX5, CPB-I, ENX2, HEL-S-7, PP4, RPRGL3}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, BID (BH3 interacting domain death agonist) [NCBI Gene 637] {aka FP497}, BIRC5 (baculoviral IAP repeat containing 5) [NCBI Gene 332] {aka API4, EPR-1}, CASP3 (caspase 3) [NCBI Gene 836] {aka CPP32, CPP32B, SCA-1}, BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}, CDKN1A (cyclin dependent kinase inhibitor 1A) [NCBI Gene 1026] {aka CAP20, CDKN1, CIP1, MDA-6, P21, SDI1}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, CASP8 (caspase 8) [NCBI Gene 841] {aka ALPS2B, CAP4, Casp-8, FLICE, MACH, MCH5}, CASP10 (caspase 10) [NCBI Gene 843] {aka ALPS2, FLICE-2, FLICE2, MCH4}
- **Diseases:** keratopathy (MESH:C562399), aniridia (MESH:D015783)
- **Chemicals:** propidium iodide (MESH:D011419), glucose (MESH:D005947), DMEM (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12795463/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12795463/full.md

## References

43 references — full list in the complete paper: https://tomesphere.com/paper/PMC12795463/full.md

---
Source: https://tomesphere.com/paper/PMC12795463